Eicosanoid production by peritoneal and splenic macrophages in mice depleted of bone marrow by 89Sr.
Previous studies showed that the prostaglandin-forming macrophages (M phi) induced in the spleens of CBA/J mice by intraperitoneal administration of Corynebacterium parvum (CP) could not be demonstrated following the depletion of bone marrow and blood monocytes with 89Sr. The present study compares prostaglandin E2 (PGE2), leukotriene C4 (LTC4), and LTB4 release by splenic and resident peritoneal M phi in 89Sr-treated mice and 88Sr controls following in vivo CP and in vitro incubation with zymosan, calcium ionophore A23187, or phorbol ester (PMA). Intraperitoneal administration of CP resulted in the appearance of PGE2- and LTB4-releasing M phi in the spleens of control but not 89Sr mice. The incorporation and quantitative distribution of 3H-arachidonic acid into membrane lipids, however, were comparable in test and control mice. Neither zymosan nor any of the other stimulatory agents was able to effect significant release of PGE2 in vitro. No release of LTC4 by splenic M phi was detectable under experimental or control conditions. In contrast, the capacity of resident peritoneal M phi to release PGE2, LTC4, and LTB4 was apparently unaffected by 89Sr-induced bone marrow and monocyte depletion with virtually no demonstrable elicitation. Resident peritoneal M phi removed after CP in such mice showed a dramatic decrease in PGE2 release when incubated in vitro with zymosan, A23187, or PMA. These results, taken with earlier findings, demonstrate characteristically different phenotypic expression of metabolism of certain eicosanoids by splenic M phi from the spleen and the peritoneal cavity and suggest in addition that the induction of PGE2-synthesizing M phi in the spleen by CP is dependent on either an immigrant cell originating in the bone marrow or a regulatory agent derived from a bone marrow cell.
D000818:Animals; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000378:metabolism; D001853:Bone Marrow / Q000528:radiation effects*; D003520:Cyclophosphamide / Q000494:pharmacology; D015232:Dinoprostone; D007975:Leukotriene B4 / Q000378:metabolism*; D008264:Macrophages / Q000378:metabolism*; D051379:Mice; D008808:Mice, Inbred CBA; D010529:Peritoneal Cavity / Q000166:cytology; D010743:Phospholipids / Q000378:metabolism; D011458:Prostaglandins E / Q000378:metabolism*; D013189:SRS-A / Q000378:metabolism*; D013154:Spleen / Q000166:cytology; D013326:Strontium Radioisotopes / Q000009:adverse effects*
D001095:Arachidonic Acids; D010743:Phospholipids; D011458:Prostaglandins E; D013189:SRS-A; D013326:Strontium Radioisotopes; D007975:Leukotriene B4; D016718:Arachidonic Acid; D003520:Cyclophosphamide; D015232:Dinoprostone